Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. Mai 2025 14:16 ET | Quelle: BrainSync

BrainSync Under Review: The Brain-Supporting Probiotic Formula for Memory & Focus

New York, May 03, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: The root causes of brain fog, forgetfulness, and lack of focus in today’s fast-paced worldHow the gut-brain axis plays...
07. November 2024 11:41 ET | Quelle: Brain & Behavior Research Foundation

Intergenerational Effects of Adversity on Mind-Body Health: Pathways Through the Gut-Brain Axis

New York, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Intergenerational Effects of Adversity on Mind-Body Health: Pathways...
20. Juli 2021 08:10 ET | Quelle: InveniAI LLC

InveniAI Announces Successful Completion of Milestone in its Collaboration with PRISM BioLab Focused on Designing Novel Inflammasome-Targeted Therapeutic Candidates

- Successful generation of INVA8003, a peptidomimetic inhibitor of PYCARD (often referred to as ASC, apoptosis-associated speck-like protein containing CARD) triggers milestone payment to PRISM BioLab...
11. Mai 2021 08:10 ET | Quelle: InveniAI LLC

InveniAI Appoints Industry Leader Dr. Salvatore Alesci as Chief Scientific Officer to Advance AI-Powered Portfolio of Assets Targeting Dysregulation of the Gut-Brain Axis

Pipeline to include new chemical entities as well as re-innovated drugs, all targeting dysregulation of the gut-brain axis and inflammasome pathways for chronic inflammatory diseasesDr. Alesci’s...
09. September 2020 08:10 ET | Quelle: InveniAI

InveniAI and PRISM BioLab Initiate a Collaboration for the Development of Therapeutic Candidates for Treatment of Gut-Related Diseases Impacted by the Gut-Brain Axis and Inflammasome Activation Pathways

Partnership with Japan-based PRISM BioLab will enable the synthesis and development of proprietary therapeutic small-molecule candidates against molecular targets identified by InveniAI’s AI platform...